BeOne Medicines AG
F:49BA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
BeOne Medicines AG
F:49BA
|
CH |
|
Advance Residence Investment Corp
TSE:3269
|
JP |
|
C
|
Coda Minerals Ltd
OTC:CODMF
|
AU |
|
Lintes Technology Co Ltd
TWSE:6715
|
TW |
|
XTI Aerospace Inc
NASDAQ:XTIA
|
US |
|
W
|
Wiit SpA
F:9PC
|
IT |
|
R
|
Resonac Holdings Corp
XMUN:SWD
|
JP |
|
T
|
Take-Two Interactive Software Inc
F:TKE
|
US |
|
A
|
Avis Budget Group Inc
XMUN:CUCA
|
US |
|
Alcon AG
SIX:ALC
|
CH |
|
J
|
JCDecaux SE
F:DCS
|
FR |
|
V
|
Volkswagen AG
PSE:VOW
|
DE |
|
W
|
Wayfair Inc
F:1WF
|
US |
|
C
|
China Resources Beer Holdings Co Ltd
XMUN:CHK
|
HK |
|
C
|
Carlisle Companies Inc
DUS:CLE
|
US |
|
P
|
Postal Realty Trust Inc
F:2WP
|
US |
|
Telefonaktiebolaget LM Ericsson
F:ERCA
|
SE |
|
Banca Mediolanum SpA
F:ME1
|
IT |
|
C
|
Carlisle Companies Inc
F:CLE
|
US |
|
Copenhagen Airports A/S
F:KLH
|
DK |
|
R
|
Radian Group Inc
SWB:RAG
|
US |
|
F
|
Federal Home Loan Mortgage Corp
DUS:FHL
|
US |
|
R
|
RH
BMV:RH
|
US |
|
China Resources Beer Holdings Co Ltd
F:CHK0
|
HK |
BeOne Medicines AG
BeiGene is a cancer drug company that discovers, develops, manufactures, and sells medicines for oncology. Its best-known products are targeted therapies and immunotherapies used to treat different kinds of blood cancers and solid tumors. The company also runs clinical trials to find new drug candidates and expand the uses of its existing medicines. BeiGene makes money mainly by selling its approved drugs through hospitals, clinics, pharmacies, and healthcare systems. It also earns income from licensing, collaboration, and development deals with other drug companies and research partners. The main customers are doctors, hospitals, and healthcare providers that prescribe or buy cancer treatments for patients. What makes BeiGene different is that it is both a research company and a commercial drug maker, with a strong focus on oncology. That matters because cancer drugs are usually sold in a highly regulated market where success depends on getting medicines approved, building trust with physicians, and proving real clinical benefit. BeiGene’s role is to turn lab research into medicines that can be sold and used in everyday cancer care.
BeiGene is a cancer drug company that discovers, develops, manufactures, and sells medicines for oncology. Its best-known products are targeted therapies and immunotherapies used to treat different kinds of blood cancers and solid tumors. The company also runs clinical trials to find new drug candidates and expand the uses of its existing medicines.
BeiGene makes money mainly by selling its approved drugs through hospitals, clinics, pharmacies, and healthcare systems. It also earns income from licensing, collaboration, and development deals with other drug companies and research partners. The main customers are doctors, hospitals, and healthcare providers that prescribe or buy cancer treatments for patients.
What makes BeiGene different is that it is both a research company and a commercial drug maker, with a strong focus on oncology. That matters because cancer drugs are usually sold in a highly regulated market where success depends on getting medicines approved, building trust with physicians, and proving real clinical benefit. BeiGene’s role is to turn lab research into medicines that can be sold and used in everyday cancer care.
Revenue beat: BeOne reported Q2 revenue of $1.7 billion, up 30% year over year, with GAAP EPS of $2.05 per ADS, up 144%.
BRUKINSA strength: BRUKINSA remained the main growth engine, with global sales above $1.2 billion and U.S. sales of $893 million, both up 31% year over year.
Guidance raised: Management lifted 2026 revenue guidance by $300 million to $6.6 billion to $6.8 billion and raised GAAP operating income guidance by $250 million to $1 billion to $1.1 billion.
Pipeline momentum: The quarter brought major clinical and regulatory progress, including FDA approval of BEQALZI in mantle cell lymphoma, positive MANGROVE data for BRUKINSA, and FDA acceptance of TEVIMBRA in HER2-positive GEA.
Commercial breadth: Growth was broad-based across geographies and products, with strong performance in Europe, China, and rest of world markets, plus continued traction from TEVIMBRA and the Amgen in-licensed portfolio.
Long-term strategy: Management emphasized BeOne’s goal of building disease franchises across hematology and solid tumors, while continuing to invest in pipeline programs and manufacturing capacity.
Investor focus: In Q&A, management said AV AMPLIFY has had little impact so far in the U.S., remained confident in CELESTIAL-301, and described MANGROVE as well received by physicians.